US 11185554
Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease
granted A61KA61K31/7024A61K45/06
Quick answer
US patent 11185554 (Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease) held by The Board of Regents of the University of Texas System expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Nov 30 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/7024, A61K45/06, A61K9/0019, A61P